Bausch Health Companies Inc (BHC)

27.76
-0.77(-2.70%)
After Hours
28.10
+0.34(+1.22%)
- Real-time Data
  • Volume:
    1,539,694
  • Bid/Ask:
    27.50/28.16
  • Day's Range:
    27.75 - 28.56

BHC Overview

Prev. Close
28.53
Day's Range
27.75-28.56
Revenue
8.48B
Open
28.5
52 wk Range
16.08-34.8
EPS
-3.6
Volume
1,539,694
Market Cap
9.96B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
2,117,740
P/E Ratio
-
Beta
1.56
1-Year Change
56.48%
Shares Outstanding
358,808,755
Next Earnings Date
Nov. 02, 2021
What is your sentiment on Bausch Health Companies Inc?
or
Market is currently closed. Voting is open during market hours.

Bausch Health Companies Inc News

Bausch Health Companies Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellNeutral

Bausch Health Companies Inc Company Profile

Bausch Health Companies Inc Company Profile

Employees
21600

Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. It also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.

Read More
  • bullish
    0
    • will look at this again at around $25, bearish till then
      0
      • sorry...who wrote the next comment.
        1
        • sing it! dreaming..... only dreaming. at what point do analyst get banned for 'fake' analysis?
          0
          • I do not trust analyst target. Last earnings did not meet analyst expectations. May be long term will reach target 90.00. I bought at 29.00 and sold at 35.00. I follow the chart and will buy again below 30.00.
            4
            • Analyst target for VRX is $90 I am in with 50 shares at $36 hoping analyst to be right this time about $90 target So should I be long on this stock ? Please share your comments
              0
              • Stay AWAY!!!!! Dangerous. Clinton will hit on Pharma constraints tonight. With 36 you will be ok in the long run, 6% as of now and have a feeling that 4% more is on the way
                0
              • Jeremiah Cox . re: "have a feeling", never be emotional about the markets.......it'd hurt you
                0
            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.